Pharma BD Deal Intelligence
GlaxoSmithKline strikes $300 million deal with 23andMe for genetics-driven drug research combining consumer genomics with pharma R&D
From Big Pharma darling to bankruptcy how 23andMe lost 99.6 percent of its value after GSK collaboration failed to deliver drug discoveries
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
GSK and 23andMe entered a 4-year exclusive collaboration to develop novel medicines and vaccines using 23andMe's human genetics database. GSK invested $300M in 23andMe equity for access to its consumer genetic data to identify drug targets. The partnership aimed to use genetic insights to improve drug development success rates across multiple therapeutic areas.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GSK plc / 23andMe, Inc. (this deal) | 2018 | $300M | 37 |
| GSK plc / SmithKline Beecham | 2000 | $12.0B | 79 |
| GSK plc / Pfizer Inc. | 2018 | $0.0M | 77 |
| GSK plc / Novartis AG | 2014 | $16.0B | 76 |
| GSK plc / Hansoh Pharmaceutical Group Co. Ltd. | 2023 | $1.7B | 74 |
| GSK plc / Nuvalent, Inc. | 2026 | $10.6B | 70 |
| GSK plc / Sierra Oncology Inc. | 2022 | $1.9B | 70 |
← Browse all deals · How we score deals
More: 2018 deals · GSK plc deals